NEW YORK (Reuters Health) – In metformin-treated patients with type 2 diabetes, exenatide twice daily improves glycemic control to the same degree as insulin aspart twice daily, but…
NEW YORK (Reuters Health) – Insulin degludec, an ultra-long-acting basal insulin, provides glycemic control in type 1 diabetes similar to that of insulin glargine but with lower occurrence…
NEW YORK (Reuters Health) – Women with polycystic ovary syndrome have increased levels of LDL-cholesterol and non-HDL-cholesterol, as well as more widely recognized alterations in triglycerides and HDL…
NEW YORK (Reuters Health) – Neither injectable nor oral contraceptives have a meaningful effect on glucose or insulin levels, researchers report in the January 2011 Obstetrics & Gynecology.…
NEW YORK (Reuters Health) – In comparison with results in adults with diabetes, hemoglobin A1c (HbA1C) testing in younger patients doesn’t have the same level of discrimination, researchers…
NEW YORK (Reuters Health) – The response rate to high-dose pulsed intravenous glucocorticoid therapy is about 80% for patients with active Graves’ orbitopathy, German clinicians report. However, they…
NEW YORK (Reuters Health) – Basal bolus glargine insulin once daily plus glulisine before meals effectively manages general surgery patients with type 2 diabetes, investigators report. Compared to…
NEW YORK (Reuters Health) – An updated guideline from the American Academy of Neurology recommends plasmapheresis for severe relapses in multiple sclerosis and other inflammatory demyelinating neurologic disorders.…
NEW YORK (Reuters Health) – Depending on the particular regimen, insulin analogs can help 35% to 64% of patients with type 2 diabetes achieve the recommended hemoglobin A1C…
NEW YORK (Reuters Health) – In a small study of pregnant women with type 1 diabetes, use of a closed-loop insulin delivery system (also known as the artificial…